Literature DB >> 30760169

Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions.

Mayank Goyal1, Mohammed Almekhlafi2, Diederik W Dippel3, Bruce C V Campbell4, Keith Muir5, Andrew M Demchuk6, Serge Bracard, Antoni Davalos7, Francis Guillemin8, Tudor G Jovin9, Bijoy K Menon10, Peter J Mitchell11, Scott Brown12,13, Philip White14, Charles B L M Majoie15, Jeffrey L Saver16, Michael D Hill17.   

Abstract

Background and Purpose- We report the relation of onset-to-treatment time and door-to-needle time with functional outcomes and mortality among patients with ischemic stroke with imaging-proven large vessel occlusion treated with intravenous alteplase. Methods- Individual patient-level data from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration were pooled from 7 trials that randomized patients to mechanical thrombectomy added to best medical therapy versus best medical therapy alone. Analysis was restricted to patients who received alteplase directly at the endovascular hospital. The primary outcome was disability defined on the modified Rankin Scale at 3 months. Results- Among 601 patients, mean age was 66.0 years (SD, 13.9), 50% were women, and median National Institutes of Health Stroke Scale score was 17. Onset-to-treatment time was median 125 minutes (interquartile range, 90-170). Door-to-treatment time was median 38 minutes (interquartile range, 26-55). Each 60-minute onset-to-treatment time delay was associated with greater disability at 90 days; the odds of functional independence (modified Rankin Scale, 0-2) at 90 days was 0.82 (95% CI, 0.66-1.03). With each 60-minute delay in door-to-needle time; the odds of functional independence was 0.55 (95% CI, 0.37-0.81) at 90 days. The absolute decline in the rate of excellent outcome (modified Rankin Scale, 0-1 at 90 days) was 20.3 per 1000 patients treated per 15-minute delay in door-to-needle time. The adjusted absolute risk difference for a door-to-needle time <30 minutes versus 30 to 60 minutes was 19.3% for independent outcome (number-needed-to-treat ≈5 to gain 1 additional good outcome). Symptomatic intracranial hemorrhage occurred in 3.4% of patients, without a significant time dependency: odds ratio, 0.74 (95% CI, 0.43-1.28). Conclusions- Faster intravenous thrombolysis delivery is associated with less disability at 3 months among patients with large vessel occlusion.

Entities:  

Keywords:  brain ischemia; humans; ischemia; stroke; thrombectomy; thrombolysis

Mesh:

Substances:

Year:  2019        PMID: 30760169     DOI: 10.1161/STROKEAHA.118.021840

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

1.  Management of intravenous thrombolysis in case of mechanical thrombectomy: global real-life data from SITS centers.

Authors:  Katharina Feil; Marianne Dieterich; Frank A Wollenweber; Niaz Ahmed; Lars Kellert
Journal:  J Neurol       Date:  2019-05-30       Impact factor: 4.849

2.  European Stroke Organisation (ESO) guidelines on mobile stroke units for prehospital stroke management.

Authors:  Silke Walter; Heinrich J Audebert; Aristeidis H Katsanos; Karianne Larsen; Simona Sacco; Thorsten Steiner; Guillaume Turc; Georgios Tsivgoulis
Journal:  Eur Stroke J       Date:  2022-02-09

3.  Neuropeptide α-Melanocyte-Stimulating Hormone Promotes Neurological Recovery and Repairs Cerebral Ischemia/Reperfusion Injury in Type 1 Diabetes.

Authors:  Rajesh Kumar Goit; Tsz Chung Ng; Ka Cheung Tam; Jessica K W Tsang; Andrew W Taylor; Amy C Y Lo
Journal:  Neurochem Res       Date:  2021-09-29       Impact factor: 3.996

4.  Relationship between primary stroke center volume and time to endovascular thrombectomy in acute ischemic stroke.

Authors:  Laura C C van Meenen; Sanne J den Hartog; Adrien E Groot; Bart J Emmer; Martin D Smeekes; Arjen Siegers; Geert Jan Kommer; Charles B L M Majoie; Yvo B W E M Roos; Adriaan C G M van Es; Diederik W Dippel; H Bart van der Worp; Hester F Lingsma; Bob Roozenbeek; Jonathan M Coutinho
Journal:  Eur J Neurol       Date:  2021-09-23       Impact factor: 6.288

5.  Analysis of Thrombolysis Process for Acute Ischemic Stroke in Urban and Rural Hospitals in Nova Scotia Canada.

Authors:  Tessa Bulmer; David Volders; Noreen Kamal
Journal:  Front Neurol       Date:  2021-03-15       Impact factor: 4.003

6.  Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design.

Authors:  Shuya Li; Bruce C V Campbell; Lee H Schwamm; Marc Fisher; Mark Parsons; Hao Li; Yuesong Pan; Yongjun Wang
Journal:  Stroke Vasc Neurol       Date:  2021-08-26

7.  Expediting workflow in the acute stroke pathway for endovascular thrombectomy in the northern Netherlands: a simulation model.

Authors:  Willemijn J Maas; Maarten M H Lahr; Maarten Uyttenboogaart; Erik Buskens; Durk-Jouke van der Zee
Journal:  BMJ Open       Date:  2022-04-06       Impact factor: 2.692

8.  Factors Associated with Unfavorable Functional Outcomes After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke.

Authors:  Nat Satumanatpan; Warinyupa Tonpho; Nutchanon Thiraratananukulchai; Pheerawat Chaichanamongkol; Pittawat Lekcharoen; Kitti Thiankhaw
Journal:  Int J Gen Med       Date:  2022-03-25

9.  Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature.

Authors:  Angelos Sharobeam; Brett Jones; Dianne Walton-Sonda; Christian J Lueck
Journal:  J Neurol       Date:  2020-03-21       Impact factor: 4.849

10.  Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study.

Authors:  Shadi Yaghi; Eva Mistry; Adam de Havenon; Christopher R Leon Guerrero; Amre Nouh; Ava L Liberman; James Giles; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Syed Daniyal Asad; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Teddy Wu; Muhib Khan; Salah Keyrouz; Karen Furie; Nils Henninger
Journal:  J Am Heart Assoc       Date:  2021-07-29       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.